Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA

Biomarkers may be useful when deciding which nonsmall cell lung cancer (NSCLC) patients may benefit from adjuvant chemotherapy following complete resection and which chemotherapeutic agents may be used preferably in individual patients in order to maximise survival. A literature search covering the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallerek, Sandra, Sørensen, Jens Benn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2015
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487808/
https://www.ncbi.nlm.nih.gov/pubmed/26028645
http://dx.doi.org/10.1183/16000617.00005814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487808/
https://www.ncbi.nlm.nih.gov/pubmed/26028645
http://dx.doi.org/10.1183/16000617.00005814

Ejemplares similares